March 11 (Reuters) - Solid Biosciences Inc SLDB.O:
SOLID BIOSCIENCES PROVIDES INTERIM POSITIVE CLINICAL UPDATE ON PHASE 1/2 INSPIRE DUCHENNE TRIAL
SOLID BIOSCIENCES INC - SGT-003 GENERALLY WELL TOLERATED WITH ENCOURAGING SAFETY PROFILE IN 40 PARTICIPANTS
SOLID BIOSCIENCES INC - ROBUST MICRODYSTROPHIN EXPRESSION AND IMPROVED MUSCLE INTEGRITY OBSERVED AFTER SGT-003 TREATMENT
SOLID BIOSCIENCES INC - ANTICIPATES DOSING FIRST PARTICIPANT IN IMPACT DUCHENNE TRIAL IN Q1 2026
SOLID BIOSCIENCES: PLANS FOR ADDITIONAL MEETINGS WITH FDA IN H1 2026 FOR GUIDANCE ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR SGT-003